Christian et al. [79] showed that BAY 2402234, an orally bioavailable, potent, selective, and a novel DHODH inhibitor, induces differentiation and exhibits monotherapy efficacy across multiple AML subtypes. This evidence concerns the gene DHODH and acute myeloid leukemia.